Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Related Articles by Review for PubMed (Select 15542776)

1.

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.

Gourdeau H, Leblond L, Hamelin B, Desputeau C, Dong K, Kianicka I, Custeau D, Boudreau C, Geerts L, Cai SX, Drewe J, Labrecque D, Kasibhatla S, Tseng B.

Mol Cancer Ther. 2004 Nov;3(11):1375-84.

2.

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

McKeage MJ, Baguley BC.

Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Review.

4.

Angiogenesis inhibitors. Drug selectivity and target specificity.

Kesisis G, Broxterman H, Giaccone G.

Curr Pharm Des. 2007;13(27):2795-809. Review.

PMID:
17897024
5.

Vascular targeting agents.

Pilat MJ, McCormick J, LoRusso PM.

Curr Oncol Rep. 2004 Mar;6(2):103-10. Review.

PMID:
14751087
6.

Modelling approaches for angiogenesis.

Taraboletti G, Giavazzi R.

Eur J Cancer. 2004 Apr;40(6):881-9. Review.

PMID:
15120043
7.

Overview of novel anticancer drug targets.

Buolamwini JK, Assefa H.

Methods Mol Med. 2003;85:3-28. Review. No abstract available.

PMID:
12710193
8.

Titanium and vanadium complexes as anticancer agents.

Kostova I.

Anticancer Agents Med Chem. 2009 Oct;9(8):827-42. Review.

PMID:
19538167
9.

Synthesis, molecular targets, and antitumor activities of substituted tetrahydro-1-oxopyrano[4,3-b][1]benzopyrans and nanogels for drug delivery.

Perchellet EM, Perchellet JP, Ganta CK, Troyer DL, Shi A, Hua DH.

Anticancer Agents Med Chem. 2009 Oct;9(8):864-76. Review.

PMID:
19538164
10.

SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity.

Uckun FM, Mao C, Jan ST, Huang H, Vassilev AO, Sudbeck EA, Navara CS, Narla RK.

Curr Opin Investig Drugs. 2000 Oct;1(2):252-6. Review.

PMID:
11249582
11.

Spongistatins as tubulin targeting agents.

Uckun FM, Mao C, Jan ST, Huang H, Vassilev AO, Navara CS, Narla RK.

Curr Pharm Des. 2001 Sep;7(13):1291-6. Review.

PMID:
11472268
12.

Chromenes: potential new chemotherapeutic agents for cancer.

Patil SA, Patil R, Pfeffer LM, Miller DD.

Future Med Chem. 2013 Sep;5(14):1647-60. doi: 10.4155/fmc.13.126. Review.

PMID:
24047270
13.

Studies on anticancer activities of lactoferrin and lactoferricin.

Yin CM, Wong JH, Xia J, Ng TB.

Curr Protein Pept Sci. 2013 Sep;14(6):492-503. Review.

PMID:
23968351
15.

Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug.

Crespo-Ortiz MP, Wei MQ.

J Biomed Biotechnol. 2012;2012:247597. doi: 10.1155/2012/247597. Epub 2011 Nov 22. Review.

16.

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.

Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK.

Chem Biodivers. 2008 Oct;5(10):2140-55. doi: 10.1002/cbdv.200890195. Review.

PMID:
18972504
17.

Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer.

Schumacher M, Kelkel M, Dicato M, Diederich M.

Biotechnol Adv. 2011 Sep-Oct;29(5):531-47. doi: 10.1016/j.biotechadv.2011.02.002. Epub 2011 Mar 1. Review.

PMID:
21371549
18.

How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs.

Marcucci F, Corti A.

Adv Drug Deliv Rev. 2012 Jan;64(1):53-68. doi: 10.1016/j.addr.2011.09.007. Epub 2011 Sep 29. Review.

PMID:
21983328
19.

Selenium. Preclinical studies of anticancer therapeutic potential.

Batist G.

Biol Trace Elem Res. 1988 Jan-Apr;15:223-9. Review.

PMID:
2484519
20.

Targeting cysteine residues of biomolecules: new approaches for the design of antiviral and anticancer drugs.

Scozzafava A, Casini A, Supuran CT.

Curr Med Chem. 2002 Jun;9(12):1167-85. Review.

PMID:
12052170
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk